MIV 711

Drug Profile

MIV 711

Alternative Names: MIV-711

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medivir AB
  • Class Antineoplastics; Osteoporosis therapies; Small molecules
  • Mechanism of Action Cathepsin K inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Osteoarthritis
  • Discontinued Bone metastases; Osteoporosis

Most Recent Events

  • 24 Oct 2017 MIV 711 receives Fast track status from the US FDA for Osteoarthritis
  • 20 Oct 2017 Efficacy data from a phase IIa trial in Osteoarthritis presented at the annual meeting of the American College for Rheumatology and and the 52nd Association of Rheumatology Health Professionals (ACR/ARHP-2017)
  • 25 Sep 2017 Adverse events and efficacy data from a phase IIa trial in Osteoarthritis released by Medivir
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top